A randomized controlled Phase II trial of vinorelbine plus capecitabine versus docetaxel plus capecitabine in anthracycline-pretreated women with metastatic breast cancer
Conclusion: NX and TX regimens are both alternative treatments for patients with anthracycline- and taxane-resistant advanced breast cancer, but the safety profile was more favorable and manageable with the NX regimen.
Trial Registrations: ClinicalTrials.gov NCT01635465. Registered 09 July 2012.
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Shufen Li Wenjing Meng Jibo Zhang Xiaojuan Xie Chunfang Hao Yongsheng Jia Zhongsheng Tong Source Type: research
More News: Anemia | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Docetaxel | Men | Statistics | Study | Taxotere | Toxicology | Women | Xeloda